SEC Form 4 · accession 0001779934-26-000004
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne McGeorge
Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 11, 2026 · 5:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 1,250 | $19.36 | A | 1,250 | D | |
| Common Stock | Aug 10, 2026 | M | 6,500 | $11.20 | A | 7,750 | D | |
| Common StockF2 | Aug 10, 2026 | S | 1,450 | $107.58 | D | 6,300 | D | |
| Common StockF3 | Aug 10, 2026 | S | 2,800 | $108.38 | D | 3,500 | D | |
| Common StockF4 | Aug 10, 2026 | S | 1,800 | $109.30 | D | 1,700 | D | |
| Common StockF5 | Aug 10, 2026 | S | 1,000 | $110.64 | D | 700 | D | |
| Common StockF6 | Aug 10, 2026 | S | 700 | $111.41 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $19.36 | Aug 10, 2026 | M | 1,250 | D | Jun 28, 2023 | Jun 27, 2032 | Common Stock | 1,250 | 0 | D |
| Stock Option (Right to Buy) | $11.20 | Aug 10, 2026 | M | 6,500 | D | May 23, 2024 | Sep 10, 2033 | Common Stock | 6,500 | 0 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.